RespiVert

What RespiVert does

RespiVert operates the OLXTOTO-branded WooCommerce website template sold as a digital product on Envato Market, positioned as a ready-to-deploy online slot gambling platform. According to the firmographics header it was founded in 2006 and is headquartered in High Wycombe, United Kingdom, with the operating web presence (respivert.com) actively marketing the OLXTOTO product targeting Indonesian online slot consumers. The data signals are materially inconsistent across sources — separate blocks describe the entity as a UK small-molecule drug-discovery company for chronic obstructive pulmonary disease, while the website scrape, detailed product/technology/pricing/customer data, and 2007 Eight Roads Ventures funding record describe a WooCommerce template business in the online gambling vertical. Given the website content and detailed data blocks represent the current, first-party operational signal, the analytical scope is grounded in the OLXTOTO template product.

The technical build is a WordPress/WooCommerce/Elementor stack with multi-vendor marketplace plugins (Dokan, WC Vendors) and aggregation integrations for slot content from PG Soft, Pragmatic, and Habanero. Registration/login pathways, WhatsApp acquisition, and Live Chat support underpin a direct-to-consumer go-to-market. Pricing is one-time/perpetual: a Regular License at $58 and an Extended Support tier at $88-$100 (12-month support option at $90-$100). Revenue mechanics combine one-time license sales, optional recurring extended-support subscriptions, and downstream gambling-platform transaction fees on the OLXTOTO template when deployed. Scale signals include 42,355+ cumulative product sales, a 5.00/5.00 rating across 75 reviews, and 802 user comments; a single historical funding event is recorded for January 2007 from Eight Roads Ventures at a $0 disclosed amount.

Name

RespiVert

Legal name

RespiVert

Website

https://respivert.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

RespiVert operates the OLXTOTO-branded WooCommerce website template sold on Envato Market, targeting Indonesian online slot gambling consumers with multi-provider slot aggregation, registration/login flows, and optional extended support subscriptions.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

COPD & Chronic Bronchitis Management (HLAKANAE)

akta.pro secondary industry

Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

Keywords

• COPD drug discovery
• Small molecule therapeutics
• Respiratory pharmaceutical research
• Pulmonary medicine development
• Medicinal chemistry services

Headquarters

HQ city

High Wycombe

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D

Revenue model

1. Digital Product Sales: Sale of WooCommerce themes and templates for online gambling platforms
2. Extended Support Subscriptions: Optional 12-month extended support packages sold alongside themes
3. Gambling Platform Services: Online slot gambling platform generating revenue from player deposits and wagering activity

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

RespiVert is a drug discovery company that discovers and develops small molecule therapeutics for the treatment of chronic obstructive pulmonary diseases (COPD). The company applies medicinal chemistry and biological screening to identify and advance novel respiratory drug candidates through early-stage pharmaceutical development.

Product overview

RespiVert appears to operate as a digital product seller on Envato Market. The primary product offered is OLXTOTO, an online slot gambling website template. The template is built using WooCommerce and includes features for slot online gaming content, customer testimonials, promotions, and login/registration functionality. No other distinct products, modules, or services are identified in the source data.

Differentiator

Problem solved

Functional benefit

Products and services

• COPD small molecule drug discovery program Early-stage discovery and development of small molecule compounds targeting chronic obstructive pulmonary disease (COPD) and related respiratory conditions, intended to be out-licensed or partnered with pharmaceutical companies for later-stage clinical and commercial advancement.

Quantifiable outcome

• 42,355+ sales transactions on theme product
• +1 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Synairgen: UK-based clinical-stage respiratory drug discovery and development company. Directly comparable as a UK-headquartered small respiratory biotech focused on novel inhaled therapeutics for chronic lung disease.
• Pulmatrix: US-based clinical-stage pulmonary biopharmaceutical company developing inhaled small molecules for COPD and other respiratory diseases. A directly comparable niche player in respiratory small-molecule drug development.
• C4X Discovery Holdings: UK-based small-molecule discovery company whose pipeline includes respiratory indications. Comparable to RespiVert as a UK platform applying computational/small-molecule discovery to chronic respiratory indications including COPD.
• Mereo BioPharma Group: UK-listed clinical-stage company that develops and partners specialty pharmaceuticals in respiratory and rare diseases, with a focus on small molecules. Comparable profile to RespiVert as a UK-based small-molecule respiratory platform reliant on partnerships for value realization.

Direct peers

• Verona Pharma: UK-based clinical-stage respiratory company that developed ensifentrine, a first-in-class dual PDE3/PDE4 inhibitor for COPD. Closely comparable to RespiVert as a small-molecule COPD-focused UK entity that attracted a major-pharma M&A outcome (acquired by Merck).
• Innoviva (formerly Theravance): Specialty respiratory company built on a small-molecule COPD franchise (in partnership with GSK for Trelegy Ellipta and Anoro). A directly comparable commercial-stage small-molecule COPD business that originated from a similar UK/US focused discovery effort.

Broad incumbents

• Boehringer Ingelheim: Major COPD incumbent through Spiriva, Spiolto, and Atrovent, with active small-molecule discovery programs in chronic respiratory disease. A logical strategic partner for early-stage COPD programs.
• AstraZeneca: Owns the Symbicort, Breztri Aerosphere, and Trixeo COPD franchises. A broad incumbent with deep respiratory development capability and a documented history of in-licensing small molecules from smaller discovery biotechs.
• GlaxoSmithKline (GSK): Global pharmaceutical incumbent with the largest COPD franchise (Advair/Trelegy/Relvar/Anoro). Operates the most relevant established commercial and development infrastructure in the COPD small-molecule space and is a likely acquirer or partner for RespiVert-type platforms.

Regional players

• Chiesi Farmaceutici: Italy-based privately held specialty pharma with a respiratory franchise (Foster, Trimbow) and active development of novel small-molecule COPD therapies. A comparable European specialty respiratory company competing in the same regional commercial landscape as RespiVert.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RespiVert